AI Medical Service

AI Medical Service (AIM) is a Japanese med-tech firm established in September 2017 with a mission to decrease the number of missed gastrointestinal (GI) cancer diagnoses globally. The company was founded by Dr. Tomohiro Tada, an experienced endoscopist and surgeon who, through his own clinical practice, identified the significant issue of overlooking cancerous lesions during endoscopic examinations. Dr. Tada, a graduate of the University of Tokyo School of Medicine, established his own gastroenterology and proctology institute in 2006, where he performs thousands of endoscopic procedures annually. This hands-on experience directly informed the company's focus on developing a solution to augment the diagnostic capabilities of the human eye.

The core of AIM's business is the development and distribution of artificial intelligence-based diagnostic support software for endoscopy. The company targets medical institutions and endoscopists, providing a tool designed to improve the early detection rates of GI cancers, including esophageal, stomach, and colorectal cancers. A key issue the company addresses is that a significant percentage of early-stage GI cancers are missed during initial screenings, which drastically impacts patient survival rates. The business model centers on the sale and likely licensing of its AI software, which integrates with existing endoscopic equipment. The company collaborates with over 100 medical institutions to source high-quality data for training its deep learning algorithms.

AIM's flagship product, an endoscopic AI system named gastroAI-model G, analyzes images in real-time during an endoscopic procedure. When the software identifies a lesion suspicious for cancer, it alerts the physician by displaying a rectangle around the area on the monitor, prompting further examination or biopsy. This system is designed to assist, not replace, the clinician's judgment. The technology has received significant regulatory acknowledgments, including Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. It has also gained regulatory approval for its gastric cancer AI in Japan in December 2023, Singapore in February 2024, and Thailand in June 2025.

Keywords: endoscopic AI, medical imaging, cancer detection, gastroenterology, diagnostic software, med-tech, artificial intelligence in healthcare, gastrointestinal cancer, clinical decision support, Dr. Tomohiro Tada, computer-aided diagnosis, deep learning, lesion detection, gastroAI, medical device, digital health, regulatory approval, FDA Breakthrough Device, stomach cancer, colorectal cancer